Use of rivastigmine or galantamine and risk of adverse cardiac events: A database study from the netherlands

American Journal of Geriatric Pharmacotherapy

Volumn 10, Issue 6, 2012, Pages 373-380

  Kröger, Edeltraut ^a   Berkers, Mieke ^b   Carmichael, Pierre Hugues ^a   Souverein, Patrick ^b   Van Marum, Rob ^c   Egberts, Toine ^b  

^a LAVAL UNIVERSITY   (Canada)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

adverse event; Alzheimer disease; AV block; cardiac event; cholinesterase inhibitors; cohort study; database study; dysrhythmia; heart failure; ischemic heart disease; myocardial infarction; syncope

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIURETIC AGENT; ANTITHROMBOCYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALANTAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NITRATE; ORAL ANTIDIABETIC AGENT; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; CARDIOVASCULAR RISK; COHORT ANALYSIS; CROSSOVER PROCEDURE; DATA BASE; DRUG EXPOSURE; DRUG USE; FAINTNESS; FEMALE; HAZARD RATIO; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NETHERLANDS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ATRIOVENTRICULAR BLOCK; CHOLINESTERASE INHIBITORS; COHORT STUDIES; CROSS-OVER STUDIES; DATABASES, FACTUAL; FEMALE; GALANTAMINE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; NETHERLANDS; PHENYLCARBAMATES; POISSON DISTRIBUTION; PROPORTIONAL HAZARDS MODELS; RISK; SYNCOPE;

EID: 84870513581     PISSN: 15435946     EISSN: 18767761     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2012.11.002     Document Type: Article

References (33)

1. World Alzheimer Report 2009, Executive Summary 2009 Alzheimer's Disease International London, UK
2. What is dementia http://www.alzheimer-nederland.nl/informatie/wat- isdementie/dementie.aspx 2011 Accessed November 12, 2012
3. C.P. Ferri, M. Prince, C. Brayne Global prevalence of dementia: a Delphi consensus study Lancet 366 2005 2112 2117
4. J. Birks Cholinesterase inhibitors for Alzheimer's disease The Cochrane Collaboration 2009 John Wiley & Sons, Ltd. Published by
5. The availability of antidementia drugs in Europe http://www. touchneurology.com/articles/availability-antidementia-drugs-europe Accessed February 20, 2011
6. I.A. Lockhart, S.A. Mitchell, S. Kelly Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence Dement Geriatr Cogn Disord 28 2009 389 403
7. Anti-Alzheimer drugs: life-threatening adverse effects Prescrire Int 16 2007 16
8. J.P. Rowland, J. Rigby, A.C. Harper, R. Rowland Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol Adv Psychiatr Treat 13 2007 178 184
9. E. Lazartigues, J.L. Freslon, T. Tellioglu Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat Eur J Pharmacol 361 1998 61 71
10. D.L. Jardine, I.C. Melton, I.G. Crozier Decrease in cardiac output and muscle sympathetic activity during vasovagal syncope Am J Physiol Heart Circ Physiol 282 2002 H1804 H1809
11. S.S. Gill, G.M. Anderson, H.D. Fischer Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study Arch Intern Med 169 2009 867 873
12. L.Y. Park-Wyllie, M.M. Mamdani, P. Li Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study PLoS Med 6 2009 e1000157
13. K. Sato, R. Urbano, C. Yu The effect of donepezil treatment on cardiovascular mortality Clin Pharmacol Ther 88 2010 335 338
14. A.T. Isik, E. Bozoglu, M.I. Naharci, S. Kilic Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease Am J Geriatr Pharmacother 8 2010 454 459
15. The PHARMO database http://www.pharmo.nl/common/page/history Accessed 22 March 2011
16. R.M. Herings, A. Bakker, B.H. Stricker, G. Nap Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts J Epidemiol Community Health 46 1992 136 140
17. ATC/DDD index 2011 http://www.whocc.no/atc-ddd-index/ Accessed 22 March 2011
18. ICD-9 codes 2009 http://icd9cm.chrisendres.com/ Accessed 16 March 2011
19. Centraal Bureau voor de Statistiek Documentatierapport Landelijke Medische Registratie (LMR) 2010 2012 Centraal Bureau voor de Statistiek the Hague and Heerlen, the Netherlands Location
20. H.S. Lau, A. de Boer, K.S. Beuning, A. Porsius Validation of pharmacy records in drug exposure assessment J Clin Epidemiol 50 1997 619 625
21. L. Nelson, C. Tanner, S. Van Den Eeden, V. McGuire Neuroepidemiology: From Principles to Practice 2004 Oxford University Press Oxford, UK
22. M. Von Korff, E.H. Wagner, K. Saunders A chronic disease score from automated pharmacy data J Clin Epidemiol 45 1992 197 203
23. E. Kroger, R. van Marum, P. Souverein, T. Egberts Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: a retrospective cohort study Drugs Aging 27 2010 663 675
24. M. Abrahamowicz, G. Bartlett, R. Tamblyn, R. du Berger Modeling cumulative dose and exposure duration provided insights regarding the associations between benzodiazepines and injuries J Clin Epidemiol 59 2006 393 403
25. M. Maclure, M.A. Mittleman Should we use a case-crossover design? Annu Rev Public Health 21 2000 193 221
26. M. Maclure The case-crossover design: a method for studying transient effects on the risk of acute events Am J Epidemiol 133 1991 144 153
27. P. Allison Survival Analysis Using SAS: A Practical Guide 1995 SAS Publishing Cary, NC
28. P. Buchhave, L. Minthon, H. Zetterberg Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia Arch Gen Psychiatry 69 2012 98 106
29. Nederlandse vereniging voor klinische geriatrie Richtlijn Diagnostiek en Medikamenteuze Behandeling van Dementie 2005 147
30. M.C. Polidori, E. Mariani, P. Mecocci, G. Nelles Congestive heart failure and Alzheimer's disease Neurol Res 28 2006 588 594
31. Centraal Bureau voor de Statistiek Ziekenhuisopnamen-hartritmestoornissen http://www.cbs.nl/nl-NL/menu/themas/gezondheid-welzijn/cijfers/extra/2010- ziekenhuisopname.htm 2011 Accessed 28 July 2011
32. L. Burghaus, C. Eggers, L. Timmermann Hallucinations in neurodegenerative diseases CNS Neurosci Ther 16 2011 1755 5949
33. A. Pariente, D.J. Sanctussy, G. Miremont-Salame Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting CNS Drugs 24 2010 55 63